A Phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and hemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction

Authors: Cristina Tita, Edward M Gilbert, Adrian B Van Bakel, Jacek Grzybowski, Garrie J Haas, Mohammad Jarrah, Stephanie H Dunlap, Stephen S Gottlieb, Marc Klapholz, Parag C Patel, Roman Pfister, Tim Seidler, Keyur B Shah, Tomasz Zieliński, Robert P Venuti, Douglas Cowart, Shi Yin Foo, Alexander Vishnevsky, Veselin Mitrovic

Conclusion: BMS-986231 demonstrated a favorable safety and hemodynamic profile in patients hospitalized with advanced heart failure. Based on preclinical data and these studies’ findings, it is possible that the hemodynamic benefits may be mediated by inotropic and/or lusitropic as well as vasodilatory effects.

For the full article click here

Back to Clinical Studies